Promising drug cocktail targets aggressive breast cancer before surgery
NCT ID NCT04877821
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 27 times
Summary
This study tested a combination of two drugs (sintilimab and anlotinib) plus standard chemotherapy given before surgery to people with early-stage triple-negative breast cancer. The goal was to see if this approach could eliminate all signs of cancer by the time of surgery. 29 participants received the treatment for about 24 weeks, then had surgery, and were followed for safety and cancer return.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE-NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
NeoSACT
Guangzhou, Guangdong, 510080, China
Conditions
Explore the condition pages connected to this study.